Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany,
Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany.
Neuroendocrinology. 2019;109(4):362-373. doi: 10.1159/000500200. Epub 2019 Apr 16.
Cushing's disease (CD) is caused by adrenocorticotropic hormone (ACTH)-secreting pituitary tumours. They express high levels of heat shock protein 90 and heat shock factor 1 (HSF1) in comparison to the normal tissue counterpart, indicating activated cellular stress.
Our objectives were: (1) to correlate HSF1 expression with clinical features and hormonal/radiological findings of CD, and (2) to investigate the effects of HSF1 inhibition as a target for CD treatment.
PATIENTS/METHODS: We examined the expression of total and pSer326HSF1 (marker for its transcriptional activation) by Western blot on eight human CD tumours and compared to the HSF1 status of normal pituitary. We screened a cohort of 45 patients with CD for HSF1 by immunohistochemistry and correlated the HSF1 immunoreactivity score with the available clinical data. We evaluated the effects of HSF1 silencing with RNA interference and the HSF1 inhibitor KRIBB11 in AtT-20 cells and four primary cultures of human corticotroph tumours.
We show that HSF1 protein is highly expressed and transcriptionally active in CD tumours in comparison to normal pituitary. The immunoreactivity score for HSF1 did not correlate with the typical clinical features of the disease. HSF1 inhibition reduced proopiomelanocortin (Pomc) transcription in AtT-20 cells. The HSF1 inhibitor KRIBB11 suppressed ACTH synthesis from 75% of human CD tumours in primary cell culture. This inhibitory action on Pomc transcription was mediated by increased glucocorticoid receptor and suppressed Nurr77/Nurr1 and AP-1 transcriptional activities.
These data show that HSF1 regulates POMC transcription. Pharmacological targeting of HSF1 may be a promising treatment option for the control of excess ACTH secretion in CD.
库欣病(CD)是由促肾上腺皮质激素(ACTH)分泌性垂体肿瘤引起的。与正常组织相比,它们表达高水平的热休克蛋白 90 和热休克因子 1(HSF1),表明细胞应激激活。
我们的目的是:(1)将 HSF1 表达与 CD 的临床特征和激素/影像学发现相关联,(2)研究 HSF1 抑制作为 CD 治疗靶点的效果。
患者/方法:我们通过 Western blot 检查了 8 个人类 CD 肿瘤中的总 HSF1 和 pSer326HSF1(其转录激活的标志物)的表达,并将其与正常垂体的 HSF1 状态进行了比较。我们通过免疫组织化学对 45 例 CD 患者进行了 HSF1 筛选,并将 HSF1 免疫反应评分与可用的临床数据相关联。我们用 RNA 干扰和 HSF1 抑制剂 KRIBB11 评估了 HSF1 沉默和 AtT-20 细胞和 4 个人类促皮质瘤原代培养物中的 HSF1 抑制作用。
我们表明,与正常垂体相比,CD 肿瘤中 HSF1 蛋白高度表达且转录活性增强。HSF1 的免疫反应评分与疾病的典型临床特征无关。HSF1 抑制降低了 AtT-20 细胞中的 proopiomelanocortin(Pomc)转录。HSF1 抑制剂 KRIBB11 抑制了 75%的人 CD 肿瘤原代细胞培养物中的 ACTH 合成。这种对 Pomc 转录的抑制作用是通过增加糖皮质激素受体和抑制 Nurr77/Nurr1 和 AP-1 转录活性介导的。
这些数据表明 HSF1 调节 Pomc 转录。HSF1 的药物靶向可能是控制 CD 中过量 ACTH 分泌的有前途的治疗选择。